Immunomodulation via chemotherapy and targeted therapy: A new paradigm in breast cancer therapy?

Breast Care

Volumn 7, Issue 4, 2012, Pages 267-272

  Stagg, John ^a   Andre, Fabrice ^b   Loi, Sherene ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

Breast cancer; Immunotherapy; Prognosis; Tumor infiltrating lymphocytes

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CALRETICULIN; CD134 ANTIGEN; CD137 ANTIGEN; CD27 ANTIGEN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; IPILIMUMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OXALIPLATIN; PACLITAXEL; PROGESTERONE RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR; PURINERGIC P2X7 RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; LYMPHOCYTIC INFILTRATION; METASTATIC MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84866894143     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000342166     Document Type: Review

References (69)

1. Sharma P, et al.: Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 2011;11:805-812.
2. Mellman I, Coukos G, Dranoff G: Cancer immunotherapy comes of age. Nature 2011;480:480-489.
3. Stagg J, Johnstone RW, Smyth MJ: From cancer immunosurveillance to cancer immunotherapy. Immunol Rev 2007;220:82-101.
4. Vesely MD, et al.: Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011;29:235- 271.
5. Schreiber RD, Old LJ, Smyth MJ: Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-1570.
6. Burnet M: Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br Med J 1957;1:841-847.
7. Shankaran V, et al.: IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001;410:1107- 1111.
8. Kaplan DH, et al.: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
9. Smyth MJ, et al.: Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med 2000;192:755-760.
10. Koebel CM, et al.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-907.
11. Matsushita H, et al.: Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012;482:400-404.
12. Galluzzi L, et al.: The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215-233.
13. Ma Y, et al.: Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011;208:491-503.
14. Mattarollo SR, et al.: Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res 2011;71:4809- 4820.
15. Ghiringhelli F, et al.: Activation of the NLRP3 inflammasome in dendritic cells induces IL-1betadependent adaptive immunity against tumors. Nat Med 2009;15:1170-1178.
16. Michaud M, et al.: Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334:1573-1577.
17. Stagg J, Smyth MJ: Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010; 29:5346-5358.
18. Beavis PA, et al.: CD73: a potent suppressor of antitumor immune responses. Trends Immunol 2012;33:231-237.
19. Ferris RL, Jaffee EM, Ferrone S: Tumor antigentargeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol 2010;28:4390-4399.
20. Park S, et al.: The therapeutic effect of anti-HER2/ neu antibody depends on both innate and adaptive immunity. Cancer Cell 2010;18:160-170.
21. Stagg J, et al.: Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti- PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci USA 2011;108:7142-7147.
22. Kohrt HE, et al.: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest 2012;122:1066-1075.
23. Wilmott JS, et al.: Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Cin Cancer Res 2012;18:1386- 1394.
24. Galon J, et al.: The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
25. Fridman WH, et al.: The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012;12:298-306.
26. Galon J, et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-1964.
27. Kohrt HE, et al.: Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2005;2:e284.
28. Curiel TJ, et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
29. Mlecnik B, et al.: Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011;29:610-618.
30. Denkert C, et al.: Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2010;28:105-113.
31. Mahmoud SM, et al.: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-1955.
32. Finak G, et al.: Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008;14:518-527.
33. Desmedt C, et al.: Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008;14:5158- 5165.
34. Ignatiadis M, et al.: Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012;30: 1996-2004.
35. Schmidt M, et al.: The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68:5405-5413.
36. Teschendorff AE, et al.: An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
37. Penn I: Tumors of the immunocompromised patient. Annu Rev Med 1988;39:63-73.
38. Chen Q, Zhang XH, Massagué J: Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 2011;20:538-549.
39. DeNardo DG, et al.: CD4+ T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009;16:91-102.
40. Filipazzi P, et al.: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte- macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007;25:2546-2553.
41. Bidwell BN, et al.: Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 2012, DOI: 10.1038/nm2830.
42. Aaltomaa S, et al.: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 1992;28A:859-864.
43. Loi S, et al.: Evaluation of the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in a phase III randomized adjuvant breast cancer (BC) trial (BIG 2-98) of node-positive (N+) BC comparing the addition of docetaxel to doxorubicin (A-T) with doxorubicin (A)-only chemotherapy (CT). J Clin Oncol 2011;29(suppl):abstr 556.
44. Loi S, et al.: Tumor PIK3CA mutations, lymphocyte infiltration, and recurrence-free survival (RFS) in early breast cancer (BC): Results from the FinHER trial. J Clin Oncol 2012;30(suppl):abstr 507.
45. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
46. Hodi FS, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-723.
47. Robert C, et al.: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-2526.
48. Fu T, He Q, Sharma P: The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy. Cancer Res 2011;71:5445-5454.
49. Gadiot J, et al.: Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2011;117:2192-2201.
50. Gao Q, et al.: Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 2009;15:971-979.
51. Sznol M, et al.: Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010;28(suppl 15s):abstr 2506.
52. Brahmer JR, et al.: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010;28:3167-3175.
53. Curran MA, et al.: PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-4280.
54. Sakuishi K, et al.: Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore antitumor immunity. J Exp Med 2010;207:2187-2194.
55. Ngiow SF, et al.: Anti-TIM3 antibody promotes T cell IFN-gamma-mediated antitumor immunity and suppresses established tumors. Cancer Res 2011;71:3540-3451.
56. Woo SR, et al.: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012;72:917-927.
57. Croft M, et al.: TNF superfamily in inflammatory disease: translating basic insights. Trends Immunol 2012;33:144-152.
58. Narazaki H, et al.: CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells. Blood 2010;115:1941-1948.
59. Palazon A, et al.: Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res 2011;71:801- 811.
60. Piconese S, Valzasina B, Colombo MP: OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205: 825-839.
61. Gangemi S, et al.: Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. J Cell Biochem 2012;113:2122-2125.
62. Teng MW, et al.: Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases. Cancer Res 2011;71:2077-2086.
63. Langowski JL, et al.: IL-23 promotes tumour incidence and growth. Nature 2006;442:461-465.
64. Singer K, et al.: Suppression of T-cell responses by tumor metabolites. Cancer Immunol Immunother 2011;60:425-431.
65. Stagg J, et al.: CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012;72:2190-2196.
66. Stagg J, et al.: CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011;71:2892-2900.
67. Stagg J, et al.: Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010;107:1547-1552.
68. Jin D, et al.: CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res 2010;70:2245-2255.
69. Wang L, et al.: CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011;121:2371-2382.